Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The Arthritis Foundation is funding a study to help predict the onset and progression of interstitial lung disease in ...

Mortality and rates of respiratory hospitalization were similar among patients with RA-ILD initiating various non-TNF inhibitor b/tsDMARDs.

A multidisciplinary approach involving both pulmonologists and rheumatologists may lead to earlier ILD diagnosis among patients with SARDs.

Cough is prevalent in patients with progressive pulmonary fibrosis (PPF) and significantly affects their quality of life.

The researchers reported, "The EUSTAR study revealed that a decline of over 10% in forced vital capacity (FVC) within one ...

Background Prior work suggests different interstitial lung diseases (ILDs) that share the radiological usual interstitial pneumonia (UIP) pattern have an overall worse prognosis. However, ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

Halo Biosciences ("Halo"), a clinical-stage biotechnology company developing extracellular matrix-targeted therapies, today ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...